Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Authors: Philippe Flandre
Journal: Annals of Internal Medicine (2011)

Letters20 September 2011Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1Philippe Flandre, PhDPhilippe Flandre, PhDFrom INSERM UMR-S 943, Hôpital Pitié-Salpêtrière and Université Pierre et Marie Curie, Paris, France.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-6-201109200-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read the recent article by Daar and colleagues (1) with great interest. A portion of the results of this important study has already been published (2), with the more recent results still raising comments and questions.As written in the article, 2 regimens will be considered equivalent if a 2-sided CI for the hazard ratio (HR) of virologic failure (VF) is entirely within the range of 0.71 to 1.40. The upper boundary of the HR of atazanavir plus ritonavir or efavirenz was 1.56 and 1.46 with abacavir–lamivudine or tenofovir disoproxil fumarate–emtricitabine, respectively.It seems that the ...References1. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445-56. [PMID: 21320923] LinkGoogle Scholar2. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-40. [PMID: 19952143] CrossrefMedlineGoogle Scholar3. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152-60. [PMID: 16522836] CrossrefMedlineGoogle Scholar4. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663-94. [PMID: 11304107] LinkGoogle Scholar5. Hoenig JM, Heisey DM. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat. 2001;55:19-24. CrossrefGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From INSERM UMR-S 943, Hôpital Pitié-Salpêtrière and Université Pierre et Marie Curie, Paris, France.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration Douglas G. Altman , Kenneth F. Schulz , David Moher , Matthias Egger , Frank Davidoff , Diana Elbourne , Peter C. Gøtzsche , Thomas Lang , and Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Eric S. Daar , Camlin Tierney , Margaret A. Fischl , Paul E. Sax , Katie Mollan , Chakra Budhathoki , Catherine Godfrey , Nasreen C. Jahed , Laurie Myers , David Katzenstein , Awny Farajallah , James F. Rooney , Keith A. Pappa , William C. Woodward , Kristine Patterson , Hector Bolivar , Constance A. Benson , Ann C. Collier , and Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Ricardo S. Kuchenbecker , Marcelo Martins Reis , and Guilherme Barreiro Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Eric S. Daar , Ann A. Collier , and Camlin Tierney Metrics Cited ByEfficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis 20 September 2011Volume 155, Issue 6Page: 402KeywordsConflicts of interestHIV-1Viral load ePublished: 20 September 2011 Issue Published: 20 September 2011 CopyrightCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...